Skip to main content

Table 1 Characteristics of included trials

From: SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis

Characteristic Number of trials (% of 87 included) or median (IQR)
Trial population, n (%)  
 Severe sepsis or septic shock 35 (40%)
 Mixed ICU population 24 (28%)
 Specific organ dysfunction 13 (15%)
 Trauma 4 (5%)
 Cardiac surgery 2 (2%)
 Other 9 (10%)
Trial intervention, n (%)  
 Drug 47 (54%)
 Treatment bundle 12 (14%)
 Device 10 (11%)
 Nutrition 8 (9%)
 Ventilation-related 4 (5%)
 Other 6 (7%)
Jadad scale, median (IQR) 3 (2 – 3)
Jadad scale ≤1, n (%) 14 (16%)
Multicenter design, n (%) 40 (46%)
Sample size per trial, median (IQR) 64 (40 – 147)
Mean or median baseline SOFA score, median (IQR) 8.5 (7 – 10)
Mortality rate, median (IQR) 28% (19% – 36%)
Primary endpoint, n (%)  
 SOFA score 19 (22%)
 Mortality 14 (16%)
 Other 36 (41%)
 Not specified 18 (21%)
  1. ICU intensive care unit, IQR interquartile range, SOFA sequential organ failure assessment